Sep 9 CIDRAP News story “HHS funds work on new anthrax antitoxin” Sep 26, 2008 (CIDRAP News) – Emergent BioSolutions announced today that it has received a $29.7 million contract from the federal government to continue work on another of its next-generation anthrax vaccine candidates. A next-generation anthrax vaccine would help the US military more easily inoculate troops. Soldiers in high-risk areas such as the Middle East typically receive six doses of BioThrax over 18 months, followed by annual boosters. The military has said a next-generation anthrax vaccine should ideally require fewer doses and have fewer side effects. Daniel J. Abdun-Nabi, Emergent’s president and chief operating officer, said in the statement that the grant is encouraged by federal support for its AV7909 anthrax vaccine candidate. “We look forward to continuing to work with the US government to advance all aspects of AV7909, as it pursues a multi-prong approach in responding to the ongoing threat of bioterrorism,” he said. On Sep 3, Emergent announced that it had won a $24.3 million federal contract for an anthrax monoclonal antibody treatment called AVP-21D9. In its statement today the company said it was also developing a polyclonal anthrax immunoglobulin candidate for intravenous treatment for patients who have anthrax infections. Emergent’s AV7909 anthrax vaccine consists of BioThrax (also known as Anthrax Vaccine Adsorbed), plus an adjuvant called CPG 7909, licensed from Pfizer, Inc. A clinical trial of CPG 7909 added to BioThrax showed that anti-protective antigen (PA) titers increased sixfold and reduced the time to peak response from 6 weeks to 3 weeks compared with BioThrax alone, Emergent said in its statement. Also, the two doses of AV7909 elicited the same anti-PA antibody levels as three doses of BioThrax. See also: Sep 26 Emergent BioSolutions press release Of the 3-year contract, $24.9 million will cover the manufacturing of clinical lots, nonclinical safety and efficacy studies, and stability studies to determine if the vaccine can be stored without refrigeration, which is a key requirement for the new vaccine, Emergent said. The remaining $4.8 million would fund a phase 1 clinical trial if the company and the government exercise that option. Emergent, based in Rockville, Md., announced the contract from the Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) in a press release today. The company makes BioThrax, the nation’s only licensed anthrax vaccine, and is also developing a recombinant anthrax vaccine and an anthrax monoclonal antibody to block the anthrax toxin.
First Published: 27th December, 2019 16:56 IST LIVE TV SUBSCRIBE TO US FOLLOW US COMMENT Former junior world champion Nikhat Zareen on Friday advanced to the 51kg category finals of the women’s boxing trials for next year’s Olympic Qualifiers after defeating Jyoti Gulia here.Zareen, a gold-medallist from the prestigious Strandja Memorial in Bulgaria, defeated Gulia, also a youth world gold-medallist and the reigning national champion, in a unanimous verdict in the opening bout of the two-day competition, which will end on Saturday.Zareen had kicked up a storm a few weeks ago by demanding a trial against iconic six-time world champion M C Mary Kom after the Boxing Federation of India’s flip-flop on the selection policy for the Olympic Qualifiers.In other bouts, world youth gold-medallist Sakshi defeated Asian silver-winner Manisha Maun in the 57kg category, while former national champion Simranjit Kaur defeated Pavitra in the 60kg opener. Both the results were unanimous verdicts.The Olympic qualifiers are scheduled to be held in China in February next year.All five categories in women’s boxing are being decided by trials as none in the 51kg, 57kg, 60kg, 69kg, and 75kg divisions managed to make the finals of the world championships. PTI SSC PMPM Last Updated: 27th December, 2019 16:56 IST Nikhat Zareen Advances To Finals Of Trials For Olympic Qualifiers Former junior world champion Nikhat Zareen on Friday advanced to the 51kg category finals of the women’s boxing trials for next year’s Olympic Qualifiers after defeating Jyoti Gulia here. WATCH US LIVE Written By Press Trust Of India